Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05074875 · ClinicalTrials.gov registry record
COVID-19 Respiratory Outcomes Registry
A clinical trial, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- 37
- Enrollment target
NCT05074875: Completed study, sponsored by Weill Medical College of Cornell University.
NCT05074875 is a clinical trial that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05074875 has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- 37 participants
- Enrollment target
Study Summary
This is a 48-week, observational study looking to see if the inflammatory process of hypoxemic respiratory failure associated with COVID-19 leads to progressive pulmonary fibrosis. Inpatient, as well as outpatient adults with recent COVID-19 hospitalization will be recruited. Data from hospitalization will be collected and subjects will return to the center for follow-up visits. Subjects will undergo the following procedures: High Resolution Computed Tomography (HRCT) of the chest, Pulmonary Function Tests (PFT), Muscle Strength Measurement, and blood draw for biomolecular data such as biomarkers found in ribonucleic acid (RNA), deoxyribonucleic acid (DNA), serum, and plasma. Quality of Life (QoL) measurements will also be collected through the study.
Primary Outcome
Categorized after exploratory analysis as improved, stable or worsened fibrotic changes seen on chest HRCT.
Interventions
- OTHER Questionnaires and Patient Reported Outcomes (PROs)
- DIAGNOSTIC_TEST Nasal Swab COVID-19 reverse transcription polymerase chain reaction test (RT-PCR)
- GENETIC Blood Samples for Biomarkers
- DIAGNOSTIC_TEST High Resolution Computed Tomography
- DIAGNOSTIC_TEST Physical Exam and Vital Signs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2021-01-15 |
| Est. Completion | 2023-05-09 |
What the finished NCT05074875 record still lists
NCT05074875 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 37 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which Questionnaires and Patient Reported Outcomes (PROs) is the first listed.
NCT05074875 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05074875 about?
NCT05074875 is a clinical study titled "COVID-19 Respiratory Outcomes Registry". This is a 48-week, observational study looking to see if the inflammatory process of hypoxemic respiratory failure associated with COVID-19 leads to progressive pulmonary fibrosis. Inpatient, as well as outpatient adults with recent COVID-19 hospitalization will be recruited. Data from hospitalizati...
What is the current status of trial NCT05074875?
This trial is currently completed. The enrollment target is 37 participants. The study started on 2021-01-15. Estimated completion is 2023-05-09.
What interventions are being tested in trial NCT05074875?
The interventions under investigation include: Questionnaires and Patient Reported Outcomes (PROs) (OTHER), Nasal Swab COVID-19 reverse transcription polymerase chain reaction test (RT-PCR) (DIAGNOSTIC_TEST), Blood Samples for Biomarkers (GENETIC), High Resolution Computed Tomography (DIAGNOSTIC_TEST), Physical Exam and Vital Signs (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05074875?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI